

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

EMILE LORIA ET AL.

Docket No.: 01-346

Serial No.:

09/867,159

Examiner :

Filed

May 29, 2001

Art Unit :

For

ANTI-ALLERGIC PHARMACEUTICAL COMPOSITION CONTAINING AT LEAST ONE ALLERGEN AND AT LEAST ONE

ANTIHISTAMINE COMPOUND

900 Chapel Street

Suite 1201

New Haven, CT 06510-2802

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS

Hon. Commissioner of Patents and Trademarks United States Patent & Trademark Office Washington, D.C. 20231

Dear Sir:

In response to the Notice to Comply with Requirement for Patent Applications containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed August 1, 2002, a copy of which is enclosed, Applicants enclose herewith a substitute computer readable form Sequence Listing.

Applicants hereby state that the content of the sequence listing information recorded in computer readable form on the attached diskette is identical to the sequence listing information on the originally filed application and thus contains no new matter.

Should the Examiner need additional information, he/she is invited to contact Applicants' attorney at the telephone number listed below.

No fee is believed to be due as a result of this response. Should the Commissioner determine that a fee is due, he is hereby authorized to charge said fee to Deposit Account No. 02-0184.

Hereby carlify that this correspondence is being deposited with the United States Pestal Service as first class mail in an envelope addressed to: Commissioner of Patents and Tandemarks, Washington. DC 20231

Respectfully submitted,

EMPLE LORIA ET AL.

August 23, 2002
(Date of Deposit)

Nicole Motzer

Name and Reg. No. of Attorney

August 23, 2002

By/ Ba

Barry L. Kelmachter

Attorney for Applicants

Area Code: 203

Telephone: 777-6628-ext. 114

Telefax : 865-0297

Date: August 23, 2002







United States Patent and Trademark Office

COMMISSIONER FOR PATENTS United States Patent and Trademark Office WASHINGTON, D.C. 20231 www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/867,159

Emile Loria

01-346

Gregory P. La Pointe BACHMAN & LaPOINTE, P.C.

Suite 1201 900 Chapel Street New Haven, CT 06510-2802

CONFIRMATION NO. 5964 **FORMALITIES LETTER**

QC000000008560538

Date Mailed: 08/01/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE